[
    [
        {
            "time": "2018-11-19",
            "original_text": "The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia",
            "features": {
                "keywords": [
                    "Alnylam",
                    "Oxluma",
                    "FDA Approval",
                    "DBV",
                    "Chief Scientific Officer",
                    "Decision Day",
                    "Liquidia"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-07",
            "original_text": "Novartis Kicks Off $2.5B Share Buyback Program On Strong Pipeline Growth",
            "features": {
                "keywords": [
                    "Novartis",
                    "Share Buyback",
                    "Pipeline Growth"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-26",
            "original_text": "Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event",
            "features": {
                "keywords": [
                    "Novartis",
                    "growing sales",
                    "margin expansion",
                    "in-market brands",
                    "pipeline"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-11-12",
            "original_text": "Mesoblast (MESO) Q1 2021 Earnings Call Transcript",
            "features": {
                "keywords": [
                    "Mesoblast",
                    "Earnings Call",
                    "Q1 2021"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 4,
                "Source_Recency": 4
            }
        }
    ]
]